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Abstract In the period from August 1991 to August 
1994, the Dutch Slide Review Committee of Adult Leu- 
kemias classified 14 leukemias as AML-M0. We re- 
viewed the clinical characteristics and response to ther- 
apy of these patients. Eight patients were male. Pa- 
tients' age ranged from 7 to 77 years (medium age 62 
years). There was a striking homogeneity in morpho- 
logical appearance of the blasts, being small to me- 
dium-sized round cells with often an eccentric nucleus 
with fine chromatin, several distinct nucleoli, and a high 
nucleo-cytoplasmic ratio. In addition to myeloid-asso- 
ciated markers such as CD13 and CD33, the blasts of 
all patients were positive for CD34 and HLA-DR,  
pointing to their immature differentiation stage. TdT 
was present in the blasts of 71%, CD7 was positive in 
the blasts of 42% of the patients. No consistent cyto- 
genetic abnormalities were found. With respect o the 
treatment outcome, four patients achieved a complete 
remission after remission-induction treatment. The me- 
dian survival was 4.5 months. Our present study shows 
AML-M0 to be an immature leukemia, uniform in mor- 
phology and immunological phenotype, with no consis- 
tent cytogenetic phenotype and with a poor clinical out- 
come. 
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there is myeloperoxidase (MPO) in more than 3% of 
the blasts, the leukemia is of myeloid origin [2, 8]. In 
the great majority of MPO-negative leukemias the lym- 
phatic origin can be confirmed by immunological mark- 
er analysis. Some of the MPO-negative leukemias, how- 
ever, are negative for lymphatic markers. These in- 
clude: acute megakaryoblastic leukemias, described in 
the FAB classification as M7 [3], and immature leu- 
kemias, which may include immature monocytic, ery- 
throid, or myeloid leukemias [1]. 
Recently, the FAB group designated leukemias with 
minimal myeloid differentiation as AML-M0 [4]. The 
diagnosis AML-M0 is made if less than 3% of the blasts 
are positive for MPO or the Sudan black B (SBB) reac- 
tion and if the blasts are positive for the myeloid-asso- 
ciated markers CD13 and/or CD33 and negative for B- 
and T-lineage markers (CD3, CD5, CD10, CD19). In 
this definition the absence of lymphatic and megaka- 
ryoblastic markers may be a stronger argument for the 
myeloid origin of the blasts than the presence of CD13 
or CD33, because these markers also may be expressed 
on nonmyeloid lineages. Leukemias that fulfill the cri- 
teria for AML-M0 may therefore be heterogeneous 
with respect o their origin. This may be reflected by 
heterogeneity in clinical presentation and behavior, as 
well as in hematological parameters. Here we describe 
these characteristics in 14 patients with an acute leu- 
kemia classified as AML-M0. 
Introduction 
The classification of acute leukemias is based mainly on 
light-microscopic morphological and cytochemical 
characteristics. According to the FAB classification, if
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Patients and methods 
In the period from August 1991 to August 1994, the diagnosis of 
acute myeloid leukemia was made for 656 patients. Fourteen pa- 
tients (2%) were considered to have AML-M0. A review of all 
peripheral blood and bone marrow smears was performed by the 
Dutch Slide Review Committee of Adult Leukemias. Morpholog- 
ical analysis was performed on slides tained with May-Grttnwald- 
Giemsa and for the SBB, nonspecific alpha-naphthyl acetate s- 
terase and periodic acid-Schiff (PAS) reaction. The immunologi- 
cal marker analysis on Ficoll-Hypaque-separated mononuclear 
cells was performed in different laboratories, all members of the 
Dutch Study Group on Immunophenotyping of Leukemias and 
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Lymphomas (SIHON), which organizes biannual quality-control 
studies [13]. All laboratories used the immunofluorescence tech- 
nique. The panel of monoclonal antibodies, as recommended by 
the SIHON, included for the B-cell lineage: CD10 and CD19; for 
the T-cell lineage: CD3, CD5 and CD7; for the myelo/monocytic 
lineage: CD13 and CD33. As markers for the blasts cells TdT, 
CD34, and HLA-DR were used. A leukemia was considered to 
be positive for a marker if more than 10% of the blasts were po- 
sitive for that marker. Cytogenetic analysis was performed in dif- 
ferent hospitals, and records from those patients who entered the 
HOVON-4 therapeutic trial on AML were reviewed by a second 
center. Seven of the patients were included in this HOVON-4 
trial. They received remission-induction therapy consisting of 
daunorubicin 45 mg/m 2 for 3 days, together with ARA-C 200 mg/ 
m 2 for 7 days. For six patients this course was followed by a sec- 
ond course consisting of AMSA 120 mg/m 2 for 3 days, together 
with ARA-C 1 g/m 2 two times a day for 6 days. Only three pa- 
tients received a third course consisting of mitoxantrone 10 mg/ 
m 2 together with etoposide 100 mg/m 2 for 5 days. Five patients 
received remission-induction therapy not according to the HO- 
VON-4 trial, consisting of daunorubicin plus ARA-C (3 patients), 
thioguanine plus ARA-C (1 patient), or etoposide, mitoxantrone, 
and ARA-C (1 patient). Two patients did not receive induction 
therapy. None of the patients was treated with a scheme used for 
acute lymphoblastic leukemias. 
Results 
Pat ient  character is t ics  
Pat ient  character ist ics  are  shown in Tab le  1. E ight  of  
the  14 pat ients  were  male.  The  med ian  age of  the  pa-  
t ients  was 62 years  ( range  7-77 years) .  A t  p resentat ion ,  
l ymphadenopathy  was found  in four  pat ients  and hepa-  
tosp lenomega ly  in four.  No  g ingival  hyper t rophy  was 
found.  
Laboratory  character ist ics  
Laboratory  character is t ics  are  also shown in Tab le  1. 
The  leukocyte  count  at p resentat ion  ranged f rom 0.7 to 
Fig. 1 Morphology of blasts in AML-M0 (May-Grttnwald-Giem- 
sa stain) 
214 x 109/1 (mean 16.7 x 109/1). Hb  ranged f rom 4.1 to 
10.5 mmol/1 (mean 6.3 mmol/1).  P la te le t  count  ranged 
f rom 8 to 201 x 109/1 (mean 83 x 109/1). 
Morpho logy  and cytogenet ics  
Bone  marrow aspirates were  hyperce l lu la r  in all pa-  
t ients and conta ined  a large number  of  leukemic  blasts 
(mean 79.4%;  range  62.0-92.6%) .  A lmost  no  matur ing  
mye lo id  cel ls were  seen. Per iphera l  blast count  ex- 
ceeded 50% in f ive of  the  14 pat ients  ( range 1-90).  The  
blasts were  smal l  to med ium-s i zed  round cel ls wi th  an 
eccentr ic  nuc leus  (Fig. 1). The  nuc leus  o f ten  had  a flat- 
Table 1 Patient characteristics, laboratory characteristics, and treatment outcome in 14 patients with AML-M0 (CR Complete remis- 
sion) 
Patient Sex Age Lymph- Hepato- Spleno- Hb WBC Plate- Response to Survival 
No. adeno- megaly megaly (mmol) ( x 109/1) lets treatment (months) 
pathy ( + 109/1) 
1 F 7 - 
2 M 62 + 
3 M 65 - 
4 F 77 - 
5 M 51 + 
6 M 60 + 
7 M 57 - 
8 F 55 - 
9 M 66 
10 F 76 
11 M 40 
12 F 25 
13 M 70 
14 F 72 
m 
+ + 4.7 1.46 68 CR after course 1 Still alive 
- - 6.0 78.6 41 No response 12 
- - 10.5 9.0 54 CR after course 3 14 
- - 7.2 1.72 155 No response 4.5 
- - 6.0 1.3 24 CR after course 1 20 
+ + 8.5 32.1 8 No treatment 3 
- - 4.1 2.9 79 No response 3 
- - 5.8 2.4 112 CR after course 1 4.5 
No CR after course 2 
+ - 5.2 8.0 12 Response unknown 1.5 
- + 6.1 2.4 54 No response 6 
- - 6.6 0.7 201 No response 2 
- - 7.1 10.5 64 CR after course 1 32 
CR after course 2 
- - 6.9 64.5 110 No response 6 
+ + 4.3 18.8 189 No treatment 3 
Tab le  2 Immuno log ica l  marker  express ion  and  cytogenet ic  analys is  of 14 pat ients  w i th  AML-M0 (ND Not  done)  
Pat ient  CD13 CD33 HLA-DR CD34 TdT  CD7 Karyotype  
No. 
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1 - + + + - + 
2 + + + + - + 
3 + ND + + ND - 
4 + - + + + - 
5 + - + + ND - 
6 + - + + + - 
7 + - + + + + 
8 + + + + + -- 
9 + + + + + - 
10 + - + + + + 
11 + + + + + + 
12 + + + + ND - 
13 + - + + + - 
14 + - + + - + 
Add (12) (p13) 
inv (3) (q21p26) 
Normal  
Normal  
Normal  
Normal  
7q-, t r i somy 13 
Normal  
ND 
De l  7, t r i somy 8 
Tr i somy 1, te t rasomy 4 
14p + 
ND 
Tr i somy 9, par t ia l  
t r i somy 1 
tened shape and was sometimes lobulated or cleaved 
and contained fine chromatin with several distinct nu- 
cleoli. The cytoplasm was lightly basophilic without 
granules. Vacuoles were seen in three patients and cy- 
toplasmic offspring in four. 
SBB staining was negative for eight patients. Alpha- 
naphthyl acetate sterase was positive for five patients 
and showed in one patient a dotlike pattern. The reac- 
tion remained positive after inhibition with natrium 
fluoride in four patients. 
Immunological marker analysis 
The results of immunological marker analysis are 
shown in Table 2. The blasts of all patients but one 
were positive for CD13; all showed CD34 and HLA- 
DR expression. No leukemias were positive for mega- 
karyoblastic markers. The blasts of three patients were 
positive for TdT and CD7. They were found to be 
MPO negative and did not express cytoplasmatic 
CD22. The blasts in two of these three patients were 
al~ negative for cytoplasmatic CD3; in one patient cy- 
to~_asmatic CD3 was not measured. 
Cylogenetic analysis 
The data of cytogenetic analysis are summarized as well 
in Table 2. No consistent chromosomal berration was 
found. 
Treatment outcome 
Treatment outcome is shown in Table 1. Four patients 
achieved complete remission after the first course of 
chemotherapy. One of these patients is still alive and in 
complete remission after 17 months. The other 13 pa- 
tients relapsed and died. The median survival time of 
the 13 patients who died was 4.5 months (range 1.5-32 
months). 
Discussion 
Although since 1991 the AML-M0 as a subtype of 
acute myeloid leukemia has been described in the FAB 
classification, the biological and clinical features are not 
yet clearly defined. Here we describe the characteristics 
in 14 patients with an acute leukemia that fulfill the cri- 
teria for AML-M0. The presenting clinical features of 
the patients were not distinctive compared with the 
other FAB subtypes, although the AML-M0 seems to 
be a leukemia of the older male patient, also described 
by Sempere t al. [10]. As in other FAB subtypes, there 
is a wide range in the leukocyte and thrombocyte 
counts at presentation. In morphological appearance, 
however, a striking homogeneity of the blasts was seen 
between patients, being small to medium-sized round 
cells. The blasts are distinguishable from lymphatic 
blasts by their fine chromatin and the presence of sev- 
eral prominent nucleoli. A second common feature is 
the high blast count in the bone marrow and the ab- 
sence of maturation. 
Immunological analysis howed that, irrespective of 
the expression of one or more myeloid markers, the 
blasts in all patients were CD34 and HLA-DR positive, 
pointing to an immature differentiation stage [6]. TdT 
was positive in the blasts of 72% of the patients, con- 
firming indeed the immature state of the cells. CD7, a 
marker found on immature blasts and on T cells, was 
found in six of the 14 leukemias, a finding comparable 
with other reports [10, 11, 15]. 
Uniformity is not confirmed by cytogenetic analysis, 
although in three patients an abnormality of chromo- 
some 7 was found, suggesting an earlier myelodysplas- 
tic syndrome. This indicates that the cytogenetic aber- 
rations found are not pathognomonic for the loss of the 
capacity of the blasts to differentiate. 
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Reaction to therapy is poor, with respect to com- 
plete remission rate and to survival time, compared 
with the other AML subtypes [12]. The majority of the 
patients in our study failed to reach complete remis- 
sion. All patients died except one, a child, now alive 17 
months after diagnosis. Other studies of AML-M0 have 
shown the same pattern [9-11, 15], complete remission 
being achieved by two of eight patients [10] and six of 
15 patients [11]. All patients but one died within 28 
months after diagnosis, with a median survival of 2 
months, in the study of Sempere et al. [10]. Stasi et al. 
found a median survival of 16 weeks [11]. In a third 
study, comprising five patients, one patient was still al- 
ive 16 months after diagnosis, the median survival of 
the other patients being 2 months [15]. 
Several factors may account for the poor outcome in 
this subtype. First, the CD34-positive cells may repre- 
sent in their population cells with stem cell characteris- 
tics. It is known that normal stem cells are in a quies- 
cent state, which make them relatively more insensitive 
to chemotherapy [14]. Second, a positive correlation 
between CD34 positivity and the presence of p-170, a 
glycoprotein that mediates multidrug resistance, is ob- 
served [5]. An increased expression of p-170 glycopro- 
tein is also seen in the blasts of refractory patients in 
other subtypes of AML [7]. 
In conclusion, our study shows that the leukemias 
classified as AML-M0 are homogeneous with respect o 
morphology, showing immature cells without signs of 
maturation, and with respect to immunophenotype, 
with positivity for CD34 and HLADR.  They have no 
consistent chromosomal aberration and have a poor 
clinical outcome compared with AML as a whole. 
If AML-M0 is to be considered as an entity, other 
immature subtypes in SBB-negative acute leukemias 
may be distinguished based on different marker expres- 
sion, e.g., lack of both lymphatic and myeloid markers. 
So far, it is not known whether the immature nonlym- 
phatic subtypes, which may be similar in morphological 
appearance and are likely to be positive for CD34 and 
HLA-DR,  differ in clinical presentation and outcome 
from AML M0. 
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